Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Free Cash Flow (2022 - 2025)

Oramed Pharmaceuticals' Free Cash Flow history spans 4 years, with the latest figure at -$2.6 million for Q4 2025.

  • For Q4 2025, Free Cash Flow changed N/A year-over-year to -$2.6 million; the TTM value through Dec 2025 reached -$6.2 million, changed N/A, while the annual FY2025 figure was -$9.2 million, 8.59% down from the prior year.
  • Free Cash Flow reached -$2.6 million in Q4 2025 per ORMP's latest filing, up from -$3.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $2.1 million in Q2 2024 to a low of -$9.2 million in Q1 2022.
  • Average Free Cash Flow over 4 years is -$4.0 million, with a median of -$2.7 million recorded in 2023.
  • The largest YoY upside for Free Cash Flow was 178.22% in 2024 against a maximum downside of 878.79% in 2024.
  • A 4-year view of Free Cash Flow shows it stood at -$8.4 million in 2022, then skyrocketed by 83.02% to -$1.4 million in 2023, then tumbled by 400.07% to -$7.1 million in 2024, then surged by 62.76% to -$2.6 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Free Cash Flow are -$2.6 million (Q4 2025), -$3.5 million (Q1 2025), and -$7.1 million (Q3 2024).